Verona Pharma PLC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Verona Pharma's General Counsel, Andrew Fisher, reported significant equity transactions following the company's acquisition via a Scheme of Arrangement.
Verona Pharma plc's President and CEO, David Zaccardelli, reported the disposition of shares and cash conversion of equity awards following the company's acquisition by Merck Sharp & Dohme LLC.
Verona Pharma's Chief Medical Officer, Kathleen A. Rickard, disposed of all her beneficial ownership in the company's shares and derivative securities following a scheme of arrangement related to an acquisition.
Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, reported the disposition of ordinary shares and conversion of equity awards into cash following the company's acquisition by Merck Sharp & Dohme LLC.
Verona Pharma director Michael Austwick reported the disposition of shares, RSUs, and options following the company's acquisition by Merck Sharp & Dohme LLC.
Verona Pharma director Anders Ullman reported the disposition of shares and derivative securities following the company's acquisition by Merck Sharp & Dohme LLC.
Verona Pharma director Mahendra Shah reports changes in beneficial ownership following the company's acquisition by Merck Sharp & Dohme LLC, converting shares and options into cash.
Verona Pharma director Vikas Sinha disposed of all his beneficial ownership in the company following its acquisition by Merck Sharp & Dohme LLC.
Verona Pharma director Lisa Deschamps reported changes in her beneficial ownership due to the company's acquisition by Merck Sharp & Dohme LLC.
Verona Pharma plc director David R. Ebsworth disposed of all beneficial ownership in the company following its acquisition by Merck Sharp & Dohme LLC.
Verona Pharma director Martin Edwards divests all holdings, including shares, RSUs, and options, following the company's acquisition by Merck Sharp & Dohme LLC.
Verona Pharma plc Director James Aloysius Brady reports significant equity and option dispositions tied to the company's acquisition by Merck Sharp & Dohme LLC.
Verona Pharma director Kenneth Cunningham reports the disposition of shares, RSUs, and options as part of the company's acquisition by Merck Sharp & Dohme LLC for $107 per ADS.
Verona Pharma director Christina Ackermann reported the disposition of ordinary shares, restricted share units, and share options following a Scheme of Arrangement related to an acquisition by Merck Sharp & Dohme LLC.
Verona Pharma's Chief Medical Officer, Kathleen A. Rickard, reported gifting 189,600 ordinary shares under a pre-arranged plan.
Verona Pharma plc's President and CEO, David Zaccardelli, reported a future gift of 1,200,000 ordinary shares, effective August 29, 2025.
Verona Pharma's Chief Financial Officer, Mark W. Hahn, reported gifting 1,200,000 Ordinary Shares on August 29, 2025.
Verona Pharma director Kenneth Cunningham acquired shares through RSU vesting and sold a portion to cover tax obligations.
Verona Pharma plc Director Lisa Deschamps reported the vesting of restricted stock units and a subsequent sell-to-cover transaction for tax obligations.
Verona Pharma's General Counsel, Andrew Fisher, reported the acquisition of shares from RSU vesting and a subsequent sell-to-cover transaction for tax obligations.
Verona Pharma's CFO, Mark W. Hahn, reported the acquisition of shares from RSU vesting and a concurrent sale to cover tax obligations on August 1, 2025.
Verona Pharma's Chief Medical Officer, Kathleen A. Rickard, acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations under a pre-arranged 10b5-1 plan.
A Verona Pharma plc director acquired shares through RSU vesting and sold a portion to cover tax obligations.
Verona Pharma director Michael Austwick acquired 24,000 shares from RSU vesting and sold 11,288 shares to cover tax obligations.
Verona Pharma plc Director James Aloysius Brady reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.
Verona Pharma's President and CEO, David Zaccardelli, acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations.
Verona Pharma plc Director David R. Ebsworth reported the vesting of restricted stock units and a subsequent sell-to-cover transaction for tax obligations.
Verona Pharma plc Director Martin Edwards reported the vesting of restricted stock units and a subsequent sell-to-cover transaction for tax obligations.
Verona Pharma plc Director Mahendra Shah sold 3,608 Ordinary Shares to cover tax obligations following the vesting of 24,000 Restricted Stock Units.
Verona Pharma Director Vikas Sinha reported the vesting of restricted stock units and a subsequent sell-to-cover transaction for tax obligations.